The best snapshots we've ever had of how this repair works
Within every living cell, a quiet war is waged against the entropy of existence — DNA breaks, and proteins labor to mend it. When the genes governing this repair, BRCA1 and BRCA2, are silenced by mutation, a backup protein called RAD52 steps in, allowing damaged cells to survive and proliferate into cancer. Researchers at Ohio State University have now captured the most detailed images ever made of this repair mechanism in action, revealing a 19-unit protein ring assembling and stitching broken DNA strands back together — a structural portrait that, for the first time, gives scientists a clear target to aim at when designing drugs to stop cancer cells from repairing themselves.
- Cancer cells carrying BRCA mutations depend on RAD52 to survive — block that protein, and those cells lose their lifeline, but doing so has required a level of structural understanding that has eluded science until now.
- The human RAD52 protein moves too fast and folds too intricately for conventional imaging, forcing researchers to study Mgm101, its ancient yeast ancestor, as a more legible stand-in for the same molecular machinery.
- Using cryogenic electron microscopy and mass spectrometry together, the team froze the repair process mid-action and captured four distinct stages — including a never-before-seen intermediate state where DNA bases sit exposed and vulnerable, waiting to be matched.
- The images resolve a long-standing debate in cancer biology: this entire repair process is orchestrated by a single 19-unit protein ring, not two, a finding that suggests the mechanism is fundamental and conserved across species.
- The next frontier is imaging human RAD52 itself at the same resolution — if that intermediate state can be mapped in the human protein, drug developers will have a precise molecular lock to design a key against.
Every day, the DNA in your cells breaks — ordinary fractures from cell division, radiation, and the simple wear of living. Proteins exist to mend these breaks, but when mutations silence the genes that make them, as happens with BRCA1 and BRCA2, cancer can take hold. Now, scientists have captured the clearest images yet of how one of these repair proteins works, opening a new path toward drugs that could stop cancer cells from surviving.
The protein is called RAD52. In cells where BRCA genes have been knocked out, RAD52 takes over the repair work, allowing damaged cells to survive when they shouldn't. Blocking it could kill those cancer cells — but blocking it requires understanding exactly how it works. The human version is too complex and too fast to image fully, so researchers at Ohio State University, led by Charles Bell, studied Mgm101, an ancestral version of RAD52 found in yeast mitochondria. It performs the same function, but is simpler and more legible.
Using cryogenic electron microscopy and mass spectrometry, the team watched Mgm101 assemble into a ring of 19 protein copies. The first strand of broken DNA slides into place around the ring, bases pointing upward and exposed. The second strand arrives, recognizes its complement, and the two zip back into a double helix. The researchers captured this entire sequence in high resolution — including a critical intermediate state, the moment when the first strand is bound but the bases are still exposed and waiting.
The images also resolved a long-standing uncertainty: this repair process requires only one protein ring, not two. That clarity suggests the mechanism is conserved across species and fundamental to cellular life. "This focuses our strategies for drug development," Bell noted. The research, published April 27, 2026, in Nucleic Acids Research, was a collaboration between Bell's lab and that of mass spectrometry specialist Vicki Wysocki, now at Georgia Tech.
The next step is capturing the same repair phases using human RAD52. If researchers can map that vulnerable intermediate state in the human protein, they will have concrete targets — a molecule that jams the ring, blocks the annealing step, or disrupts the intermediate could kill cancer cells that depend on RAD52 to survive. For patients with BRCA mutations, for whom options remain limited, that possibility is worth watching closely.
Every day, the DNA in your cells breaks. Not catastrophically—just the ordinary fractures that happen when cells divide, when they're exposed to radiation, when the machinery of life simply wears on itself. Cells have proteins to fix these breaks, to stitch the strands back together and keep everything running. But when those proteins fail, when mutations silence the genes that make them, cancer can take hold. This is what happens in BRCA1 and BRCA2 mutations, which sharply raise the risk of breast, ovarian, and other cancers. Now, scientists have captured the clearest images yet of how one of these repair proteins actually works—and in doing so, they've opened a new path toward drugs that could stop cancer cells from surviving.
The protein in question is called RAD52. In cells where BRCA genes have been knocked out by mutation, RAD52 takes over the repair work, allowing damaged cells to survive and multiply when they shouldn't. If you could block RAD52, you could kill those cancer cells. But blocking it requires understanding exactly how it works, and that's been nearly impossible to see. The human version of the protein is too complex, too fast, too intricate for even the most sophisticated imaging equipment to capture in full detail. So researchers at Ohio State University, led by Charles Bell, a professor of biological chemistry and pharmacology, took a different approach. They studied Mgm101, an ancestral version of RAD52 that lives in yeast mitochondria. It does the same job, but it's simpler, older, more legible.
What they found was striking. Using advanced techniques—cryogenic electron microscopy to freeze proteins in solution and observe their structure, combined with mass spectrometry to measure how proteins and DNA bind together—the team watched Mgm101 assemble itself into a ring made of 19 copies of the protein. This ring acts as a template. The first strand of broken DNA slides into place around it, held only by its sugar-phosphate backbone, with the genetic bases pointing upward and completely exposed. Then the second strand arrives and begins to anneal, or fuse, with the first. The two strands find each other, recognize each other, and zip back together into the classic double helix. The researchers captured this entire process in high resolution: the empty ring, the ring with one strand attached, the intermediate state where both strands are present but not yet fully bonded, and finally the repaired DNA released as a complete, functional molecule.
What makes this breakthrough significant is what it reveals about the mechanism itself. For years, the field wasn't certain whether this repair process required one protein ring or two. These images show it's one—a single molecular complex orchestrating the whole repair. That clarity matters because it suggests this mechanism is conserved across species, that it's fundamental to how cells work. It also provides something the field has never had before: a detailed view of the intermediate state, the moment when the first strand is bound but the bases are still exposed and vulnerable, waiting to be matched with their complement. "It's still a proposed mechanism," Bell said in a statement. "Just because we see these snapshots of the process doesn't mean we know all the details, but we do have the best snapshots for any protein that does this single-strand annealing. This focuses our strategies for drug development."
The research, published on April 27, 2026, in Nucleic Acids Research and designated as a Breakthrough Article, was a collaboration between Bell's lab at Ohio State and the lab of Vicki Wysocki, a professor emerita at Ohio State now at Georgia Tech, who specializes in the mass spectrometry techniques that revealed how the protein-DNA complexes assemble and bind. The work was supported by the National Science Foundation and the National Institutes of Health, with imaging conducted at Ohio State's Center for Electron Microscopy and Analysis.
The next step is to capture the same phases of the repair process using human RAD52, the actual protein that matters for cancer treatment. If researchers can see how the human version works—particularly that intermediate state where the DNA bases are exposed—they'll have concrete targets for drugs. A molecule that could jam up that intermediate, or prevent the ring from forming, or block the annealing step, could kill cancer cells that depend on RAD52 to survive. For patients with BRCA mutations, for whom options remain limited, that possibility represents something worth watching closely.
Citações Notáveis
Just because we see these snapshots of the process doesn't mean we know all the details, but we do have the best snapshots for any protein that does this single-strand annealing. This focuses our strategies for drug development.— Charles Bell, professor of biological chemistry and pharmacology at Ohio State University
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that they used yeast instead of human cells? Isn't that just a workaround?
It's more elegant than that. The yeast protein does the exact same job, but it's simpler—fewer moving parts, older in evolutionary time. That simplicity lets you see the mechanism clearly. You can't photograph a blur; you need something still enough to image.
So they're saying the human version works the same way?
They're saying it likely does, yes. But they haven't proven it yet. That's the next phase—to watch RAD52 do this in human cells and confirm that the ring structure, the intermediate state, all of it translates across species.
What's the intermediate state, exactly?
It's the moment between breaking and fixing. The first DNA strand is wrapped around the protein ring, but the genetic bases—the letters of the code—are pointing straight up, exposed and unmatched. Then the second strand comes in and starts matching up with those bases. It's never been seen before in this kind of detail.
And that matters for drug development how?
Because now you know where to aim. If you can design a molecule that prevents the ring from forming, or that jams up that intermediate state, you can stop the repair. Cancer cells with broken BRCA genes depend on RAD52 to survive. Block RAD52, and you kill the cancer.
How soon could a drug like that exist?
That's the honest answer: we don't know. They've given drug developers a much clearer target, but translating that into a therapy takes years of work. What they've done is remove one major obstacle—the uncertainty about how the mechanism actually works.